Section of Pharmacology, Department of Pharmacy and Drug Sciences, University of Bari "Aldo Moro", 70121 Bari, Italy.
Int J Mol Sci. 2024 Sep 8;25(17):9727. doi: 10.3390/ijms25179727.
Hypertriglyceridemia therapy is essential for preventing cardiovascular diseases. Fibrates belong to an important class of lipid-lowering drugs useful for the management of dyslipidaemia. By acting on the peroxisome proliferator-activated receptor (PPAR)-α, these drugs lower serum triglyceride levels and raise high-density lipoprotein cholesterol. Fibrate monotherapy is associated with a risk of myopathy and this risk is enhanced when these agents are administered together with statins. However, whereas gemfibrozil can increase plasma concentrations of statins, fenofibrate has less influence on the pharmacokinetics of statins. Pemafibrate is a new PPAR-α-selective drug considered for therapy, and clinical trials are ongoing. Apart from this class of drugs, new therapies have emerged with different mechanisms of action to reduce triglycerides and the risk of cardiovascular diseases.
高甘油三酯血症的治疗对于预防心血管疾病至关重要。贝特类药物属于一类重要的降脂药物，可用于治疗血脂异常。通过作用于过氧化物酶体增殖物激活受体（PPAR）-α，这些药物可降低血清甘油三酯水平并升高高密度脂蛋白胆固醇。贝特类药物单药治疗与肌病风险相关，当这些药物与他汀类药物联合使用时，风险会增加。然而，尽管吉非贝齐会增加他汀类药物的血药浓度，但非诺贝特对他汀类药物的药代动力学影响较小。帕拉米韦是一种新的被认为具有治疗作用的 PPAR-α 选择性药物，正在进行临床试验。除了这类药物外，还出现了具有不同作用机制的新疗法来降低甘油三酯和心血管疾病的风险。
